Article
Clinical Neurology
Nunu Laura Timotheussen Lund, Anja Sofie Petersen, Rolf Fronczek, Jacob Tfelt-Hansen, Andrea Carmine Belin, Tore Meisingset, Erling Tronvik, Anna Steinberg, Charly Gaul, Rigmor Hojland Jensen
Summary: The current treatment for cluster headache is based on trial-and-error methods and lacks specific preventive options. The impact of cluster headache on personal life is significant, with high costs and limited treatment options. There is a need for novel and targeted preventive modalities to suppress the severe pain attacks for people with cluster headache.
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Clinical Neurology
Giada Giuliani, Maurizio Gorgoni, Marta Altieri, Vittorio Di Piero
Summary: In this case study, a patient with episodic cluster headache experienced sleep disturbances after starting verapamil therapy. The sleep alterations may reflect the involvement of the hypothalamus in the pathophysiology of cluster headache. Therefore, the appearance of sleep disturbances should be considered as a warning sign of an active cluster bout.
FRONTIERS IN NEUROLOGY
(2023)
Editorial Material
Clinical Neurology
Paolo Martelletti, Martina Curto
Summary: Cluster headache often suffers from a 60-month delay in diagnosis, despite its simple yet dramatic clinical manifestations. Older drugs, while effective, also come with a high rate of adverse events, discouraging many from their appropriate use. The availability of new drug classes like monoclonal antibodies for CGRP raises concerns about access, potentially leading to progression from episodic to chronic and then to refractory forms of the condition.
Article
Pharmacology & Pharmacy
Fabrizio Benedetti, Martina Amanzio, Fabio Giovannelli, Karen Craigs-Brackhahn, Aziz Shaibani
Summary: This study revealed that participants who read a list of possible adverse events before receiving a placebo treatment reported more adverse events compared to those who did not read the list. Moreover, increased activity in the hypothalamic-pituitary-adrenal axis and higher state anxiety scores were observed in those who reported multiple adverse events, indicating a potential neuroendocrine mechanism following placebo administration.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Clinical Neurology
Anja Sofie Petersen, Mads Barloese, Nunu Lund, Adam Friis Pedersen, Marie-Louise Kulas Soborg, Mona Ameri Chalmer, Ida Callesen, Bendik Slagsvold Winsvold, John-Anker Zwart, Sisse Rye DBDS Genomic Consortium, Sisse Rye Ostrowski, Ole Birger Pedersen, Finn Sellebjerg, Helle Bach Sondergaard, Malene Bredahl Hansen, Rigmor Hojland Jensen, Thomas Folkmann Hansen
Summary: This study investigated the association between polygenetic risk, functional variants of CYP3A4, and treatment response in cluster headache patients. The results showed that the response to oxygen, triptans, and verapamil was associated with the chronicity of cluster headache, but not with a high genetic risk. The response to verapamil was also not influenced by functional variants of CYP3A4. Furthermore, no support was found for the genetic variants previously reported to be associated with treatment response. Overall, this study suggests that the clinically relevant variation in treatment response in cluster headache is not influenced by genetic factors.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Alessandra Pistolesi, Daniela Buonvicino, Mirko Muzzi, Matteo Urru, Alberto Chiarugi
Summary: This study investigated the effects of verapamil, lithium, and prednisone on hypothalamic genes. The results showed that these drugs did not affect clock genes in the anterior hypothalamus, but altered the expression of neuropeptides in the lateral hypothalamus. They did not have an effect on neurohypophyseal hormones in the posterior hypothalamus. However, amitriptyline reduced the mRNA levels of clock genes and neurohypophyseal hormones.
Editorial Material
Clinical Neurology
Daniel N. Lax, Marielle Kabbouche, Joanne Kacperski, Andrew D. Hershey
Summary: This study discusses the importance of recognizing primary headache disorders other than migraines in children and adolescents. It presents a case of an adolescent with two different headache phenotypes and provides a guided discussion on differential diagnoses, workup, treatments, and further management considerations.
Article
Immunology
Chae Won Lee, Soonok Sa, Myunghee Hong, Jihyun Kim, Sung Ryul Shim, Hyun Wook Han
Summary: A recent study compared the incidence of adverse events in adolescents and adults after vaccination with COVID-19 vaccine BNT162b2 (Pfizer-BioNTech). The study found that the risk of myocarditis or pericarditis among adolescents was significantly higher in men than in women, especially after the second dose of the vaccine. Additionally, severe adverse events such as multisystem inflammatory syndromes were significantly higher in adolescents than in adults.
Review
Pharmacology & Pharmacy
G. Pompilio, A. Migliore, D. Integlia
Summary: A systematic literature review and network meta-analysis compared the efficacy of galcanezumab with other drugs for preventing episodic cluster headaches, suggesting that galcanezumab may be more effective and should be further studied in head-to-head RCTs.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Medicine, General & Internal
Roemer B. Brandt, Leopoldine A. Wilbrink, Ilse F. de Coo, Joost Haan, Wim M. Mulleners, Frank J. P. M. Huygen, Erik W. van Zwet, Michel D. Ferrari, Rolf Fronczek
Summary: ONS is a safe, well-tolerated and long-term effective treatment for medically intractable chronic cluster headache.
Article
Oncology
Susan M. O'Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda
Summary: BTK inhibitors, such as ibrutinib and acalabrutinib, have been approved for the treatment of B cell malignancies, but have different adverse event profiles and indications. Acalabrutinib, as a second-generation BTK inhibitor, is associated with fewer cases of atrial fibrillation and mainly grade 1-2 headaches compared to ibrutinib. Zanubrutinib, a next-generation BTK inhibitor, is currently approved for MCL treatment but under investigation for CLL.
FRONTIERS IN ONCOLOGY
(2021)
Article
Clinical Neurology
Alexandra N. Cocores, Peter J. Goadsby, Teshamae S. Monteith
Summary: This study assessed the characteristics and associated disability of headache as an adverse event following vaccination. Headache is a common symptom of vaccines, but there is a lack of systematic investigations on post-licensure reports of this adverse event.
Article
Clinical Neurology
Byung-Su Kim, Pil-Wook Chung, Byung-Kun Kim, Mi Ji Lee, Min Kyung Chu, Jin-Young Ahn, Dae Woong Bae, Tae-Jin Song, Jong-Hee Sohn, Kyungmi Oh, Daeyoung Kim, Jae-Moon Kim, Jeong Wook Park, Jae Myun Chung, Heui-Soo Moon, Soohyun Cho, Jong-Geun Seo, Soo-Kyoung Kim, Yun-Ju Choi, Kwang-Yeol Park, Chin-Sang Chung, Soo-Jin Cho
Summary: Delay in diagnosis may increase the disease burden for patients with cluster headache. However, the rate of delayed diagnosis has gradually improved over time and with the publication of diagnostic criteria, highlighting the clinical significance of diagnostic clinical criteria and headache education in reducing the disease burden of cluster headache.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Diana Y. Wei, Peter J. Goadsby
Summary: The study shows that nitroglycerin is effective in inducing cluster headache attacks, cranial autonomic symptoms, and non-headache symptoms in cluster headache patients.
Chronic cluster headache patients have a slower response to nitroglycerin, while episodic cluster headache patients are more likely to experience headache attacks after receiving nitroglycerin.
Review
Clinical Neurology
David W. Dodick, Peter J. Goadsby, Messoud Ashina, Cristina Tassorelli, Hans-Peter Hundemer, Jennifer N. Bardos, Richard Wenzel, Phebe Kemmer, Robert Conley, James M. Martinez, Tina Oakes
Summary: This article reviews the challenges in clinical trials for preventive treatment of cluster headache (CH) and highlights considerations for future studies. Current guidelines for CH treatment are largely based on off-label therapies supported by limited randomized controlled trials.
Article
Medicine, General & Internal
Michel Lanteri-Minet, Serge Perrot
CURRENT MEDICAL RESEARCH AND OPINION
(2019)
Article
Clinical Neurology
L. Bendtsen, J. M. Zakrzewska, J. Abbott, M. Braschinsky, G. Di Stefano, A. Donnet, P. K. Eide, P. R. L. Leal, S. Maarbjerg, A. May, T. Nurmikko, M. Obermann, T. S. Jensen, G. Cruccu
EUROPEAN JOURNAL OF NEUROLOGY
(2019)
Article
Anesthesiology
Serge Perrot, Michel Lanteri-Minet
EUROPEAN JOURNAL OF PAIN
(2019)
Review
Infectious Diseases
S. Ranque-Garnier, C. Eldin, C. Sault, D. Raoult, A. Donnet
MEDECINE ET MALADIES INFECTIEUSES
(2019)
Article
Economics
Anne Donnet, Corinne Emery, Samia Aly, Bashar Allaf, Fanny Cayre, Nicolas Mahieu, Julie Gourmelen, Pierre Levy, Francis Fagnani
JOURNAL OF MEDICAL ECONOMICS
(2019)
Letter
Clinical Neurology
Sylvain Redon, Maya Elziere, Isabelle Lambert, Anne Donnet
ACTA NEUROLOGICA BELGICA
(2020)
Review
Oncology
Jacques Medioni, Gisele Pickering, Claire Delorme, Thibaud Lansaman, Michel Lanteri-Minet, Antoine Legras, Malou Navez, Michel Prudhomme, Alain Serrie, Eric Viel, Serge Perrot
BULLETIN DU CANCER
(2019)
Article
Clinical Neurology
Sylvain Redon, Maya Elziere, Elsa Kaphan, Anne Donnet
Letter
Clinical Neurology
Sylvain Redon, Anne Donnet
Review
Clinical Neurology
X. Moisset, M. Lanteri-Minetz, D. Fontaine
JOURNAL OF NEURAL TRANSMISSION
(2020)
Article
Multidisciplinary Sciences
Caroline Bonnet, Jizhe Hao, Nancy Osorio, Anne Donnet, Virginie Penalba, Jerome Ruel, Patrick Delmas
NATURE COMMUNICATIONS
(2019)
Review
Clinical Neurology
X. Moisset, D. Bouhassira, J. Avez Couturier, H. Alchaar, S. Conradi, M. H. Delmotte, M. Lanteri-Minet, J. P. Lefaucheur, G. Mick, V Piano, G. Pickering, E. Piquet, C. Regis, E. Salvat, N. Attal
REVUE NEUROLOGIQUE
(2020)
Review
Clinical Neurology
G. Demarquay, X. Moisset, M. Lanteri-Minet, S. de Gaalon, A. Donnet, P. Giraud, E. Guegan-Massardier, C. Lucas, J. Mawet, C. Roos, D. Valade, A. Ducros
Summary: The French Headache Society has proposed updated guidelines for managing migraines, focusing on diagnosis, risk factors, treatment efficacy, and follow-up plans. Recommendations include precise diagnosis based on ICHD-3 criteria, assessment of disability using HIT-6, checking for factors increasing chronic migraine risk, evaluating current treatments with M-TOQ, and providing strategies for pharmacological and non-pharmacological treatments.
REVUE NEUROLOGIQUE
(2021)
Review
Clinical Neurology
A. Ducros, S. de Gaalon, C. Roos, A. Donnet, P. Giraud, E. Guegan-Massardier, M. Lanteri-Minet, C. Lucas, J. Mawet, X. Moisset, D. Valade, G. Demarquay
Summary: This article presents the updated French guidelines for the management of migraine, focusing on pharmacological treatment including acute attacks, prophylaxis, and special considerations for women. The guidelines provide recommendations for different situations encountered in clinical practice, offering guidance for healthcare providers and patients.
REVUE NEUROLOGIQUE
(2021)
Article
Neurosciences
Aurelie Leplus, Michel Lanteri-Minet, Anne Donnet, Nelly Darmon, Jean Regis, Denys Fontaine
Summary: This study aims to evaluate the feasibility and safety of combining ACC-DBS and thalamic DBS for the treatment of refractory chronic unilateral neuropathic pain. It will assess the efficacy of this combination therapy compared to thalamic DBS alone, and evaluate the safety through neurological, psychiatric, cognitive, and affective function assessments.